Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...
24/7 Wall St. on MSN
Did Eli Lilly Just Find the Holy Grail of Weight Loss?
Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...
Amazon S3 on MSN
Eli Lilly’s new pill keeps the weight off
Eli Lilly said its experimental daily obesity pill helped patients maintain most of their weight loss after switching from ...
The pills are expected to cost much less then shots of blockbuster drugs like Zepbound and Wegovy. Mr. Funk was the managing ...
Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
The growth potential of the weight-loss market could explode with advances, notably GLP-1 pills, and broader insurance ...
Transforming US drug access and production: MFN pricing deals and historic manufacturing investments
In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...
Everyday Health on MSN
After GLP-1 Shots, This New Pill Helped People Keep the Weight Off
People who switched to the experimental daily GLP-1 pill orforglipron were able to maintain their weight loss after stopping ...
Bank of America reaffirmed its Buy rating for Eli Lilly, setting a price target of $1,268. Analyst Jason Gerberry noted that the trial data strengthens the company's competitive stance against rival ...
President Donald Trump announced nine of the largest drugmakers in the U.S. and Europe agreed to voluntarily sell their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback